title: Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma.
abstract: BACKGROUND
  The expression of myeloid cell leukemia 1 (Mcl-1) and p53 proteins was investigated for clinicopathological and prognostic significance in patients with gastric carcinoma.
  
  
  METHODS
  Mcl-1 protein was immunohistochemically examined in 182 patients with gastric carcinoma. The overexpression of p53 was also analyzed in T3 gastric carcinomas.
  
  
  RESULTS
  The expression of Mcl-1 was detected in 127 (69.8%) patients with gastric carcinoma. Mcl-1 was detected significantly more frequently in the undifferentiated type ( P < 0.05) and in the advanced stage of disease ( P < 0.05). The prognosis of patients with an Mcl-1-positive tumor was significantly worse than that of those with an Mcl-1-negative tumor ( P < 0.05). Multivariate analysis revealed that the expression of Mcl-1 was an independent prognostic factor, as were lymph node metastasis and tumor size. There was no significant relationship between the expression of Mcl-1 and p53. In patients with T3 gastric carcinoma who underwent curative surgery; however, Mcl-1(-)/p53 (-) tumor demonstrated the best postoperative survival rate, whereas Mcl-1(+)/p53(+) tumor had the worst.
  
  
  CONCLUSIONS
  The expression of Mcl-1 is an indicator of tumor progression and postoperative recurrence in patients with gastric carcinoma. Combined analysis of Mcl-1 and p53 proteins may accurately predict the survival of patients with T3 gastric carcinoma.
authors.affiliation: Department of Surgery, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan.
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Maeta
authors.forename: Shunichi
authors.initials: S
authors.lastname: Tsujitani
authors.forename: Sachiko
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Kenichi
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tatebe
authors.forename: Akira
authors.initials: A
authors.lastname: Kondo
authors.forename: Masahide
authors.initials: M
authors.lastname: Ikeguchi
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Kaibara
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D005819:Genetic Markers; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009363:Neoplasm Proteins / Q000032:analysis* / Q000276:immunology; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis* / Q000276:immunology; D013274:Stomach Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000276:immunology
chemical_list: D005819:Genetic Markers; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53